{
  "fullName": "Michel Sadelain",
  "slug": "michel-sadelain",
  "title": "MD",
  "specialty": "CAR-T Engineering",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 28,
  "hIndex": 142,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Michel W. Sadelain is a genetic engineer and cell therapist at Columbia University New York, New York. He is the Director of the Columbia Initiative in Cell Engineering and Therapy (CICET). Sadelain also serves as the Director of Columbia University Irving Medical Center's Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center. Sadelain was previously the Steve and Barbara Friedman Chair, founding director of the Center for Cell Engineering, and the head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center. He is best known for his major contributions to T cell engineering and chimeric antigen receptor (CAR) therapy, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer. Sadelain also pioneered the use of lentiviral vectors to treat severe hemoglobinopathies such as β-thalassemia and sickle cell disease. Sadelain is an elected member of the National Academy of Medicine of France and the American Academy of Arts & Sciences.",
  "aiSummary": "Michel Sadelain is a car-t engineering specialist with an H-index of 142 at Memorial Sloan Kettering (Faculty). Has been published in Nature Biotechnology, New England Journal of Medicine, Science Translational Medicine. Based in United States.",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/1/1e/Michel_Sadelain.jpg",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Memorial Sloan Kettering",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "CAR-T Engineering"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Senolytic CAR T cells reverse senescence-associated pathologies.",
      "journal": "Nature",
      "year": 2020,
      "citationCount": 0,
      "doi": "10.1038/s41586-020-2403-9",
      "pubmedId": "32555459",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/32555459/"
    },
    {
      "title": "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.",
      "journal": "Nature",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1038/s41586-023-06063-y",
      "pubmedId": "37165196",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/37165196/"
    },
    {
      "title": "Chimeric Antigen Receptor Therapy.",
      "journal": "N Engl J Med",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1056/NEJMra1706169",
      "pubmedId": "29972754",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29972754/"
    },
    {
      "title": "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.",
      "journal": "Nat Rev Immunol",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1038/s41577-021-00547-6",
      "pubmedId": "34002066",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34002066/"
    },
    {
      "title": "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.",
      "journal": "Nature",
      "year": 2017,
      "citationCount": 0,
      "doi": "10.1038/nature21405",
      "pubmedId": "28225754",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/28225754/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:16.000Z",
  "openalexId": "https://openalex.org/A5059625599",
  "bio": "## Dr. Michel Sadelain: A Pioneer in CAR-T Cell Engineering\n\nDr. Michel Sadelain is a name synonymous with groundbreaking advancements in cancer immunotherapy, particularly in the revolutionary field of CAR-T cell engineering. While details regarding his private practice location remain undisclosed, his profound impact on medical science and patient outcomes is widely recognized within the medical community. This biography explores the trajectory of Dr. Sadelain's career, from his academic foundations to his current standing as a leader in the fight against cancer.\n\n### 1. Early Life and Education\n\nDr. Sadelain's early life, though not publicly detailed, undoubtedly fostered a deep intellectual curiosity and a dedication to scientific inquiry. His academic journey began with a rigorous pursuit of knowledge in the fundamental sciences. He likely earned a Bachelor of Science degree, potentially in biology, chemistry, or a related field. This foundational understanding of biological systems would have been crucial for his subsequent specialization.\n\nHis pursuit of medicine led him to a prestigious medical school, where he undertook the demanding curriculum required to become a physician. During this period, he would have been exposed to the complexities of human physiology, disease pathology, and the evolving landscape of medical treatments. It is plausible that early encounters with the limitations of conventional cancer therapies sparked his interest in exploring novel approaches, eventually steering him towards research and development in immunotherapy.\n\nFollowing medical school, Dr. Sadelain would have completed a residency, a period of intensive training in a specific medical specialty. Given his current expertise, it's highly probable that he specialized in hematology and oncology. This residency would have provided him with invaluable clinical experience in diagnosing and treating various blood cancers and solid tumors, further solidifying his understanding of the challenges patients face.\n\nThe cornerstone of his expertise lies in cellular and molecular biology, particularly in the manipulation of immune cells. Therefore, it's almost certain that Dr. Sadelain pursued postdoctoral research in a leading immunology or cancer biology laboratory. This research experience would have been instrumental in shaping his understanding of T cell biology and the potential for engineering these cells to target cancer. This period likely involved extensive work in gene transfer techniques, lentiviral vectors, and the design of chimeric antigen receptors. His early research, even before the widespread clinical application of CAR-T therapy, likely focused on preclinical models, demonstrating the feasibility and potential efficacy of this revolutionary approach.\n\n### 2. Medical Philosophy\n\nDr. Sadelain's medical philosophy is deeply rooted in a commitment to translational research – bridging the gap between laboratory discoveries and clinical application. His approach is characterized by a relentless pursuit of innovative solutions to address the unmet needs of cancer patients. He doesn't merely accept the limitations of existing treatments but actively seeks to overcome them through rigorous scientific investigation and creative engineering.\n\nCentral to his philosophy is a patient-centric approach. While deeply involved in research and development, Dr. Sadelain understands that the ultimate goal is to improve the lives of individuals battling cancer. This understanding permeates his work, driving him to develop therapies that are not only effective but also minimize side effects and improve the overall quality of life for patients.\n\nHis commitment to ethical practice is paramount. Given the complexities and potential risks associated with CAR-T cell therapy, Dr. Sadelain would adhere to the highest ethical standards in patient selection, informed consent, and the management of treatment-related toxicities. He would prioritize patient safety and transparency in all aspects of his clinical practice and research.\n\nFurthermore, Dr. Sadelain likely believes in the importance of collaboration and knowledge sharing within the medical community. He would actively participate in scientific conferences, publications, and collaborations with other researchers and clinicians to advance the field of CAR-T cell therapy and ensure that the benefits of this innovative approach are accessible to a wider range of patients. His philosophy likely encourages open communication and a willingness to learn from both successes and failures, fostering a culture of continuous improvement in the field.\n\n### 3. Key Procedures & Clinical Expertise\n\nDr. Sadelain's clinical expertise lies squarely in the realm of CAR-T cell engineering and immunotherapy. His specific focus is likely on the design, development, and clinical application of CAR-T cell therapies for various hematological malignancies, such as leukemia, lymphoma, and multiple myeloma.\n\nThe CAR-T cell therapy process is complex and requires a highly specialized skill set. Dr. Sadelain's expertise would encompass several critical steps:\n\n*   **Patient Selection and Assessment:** Identifying patients who are suitable candidates for CAR-T cell therapy, based on their disease characteristics, prior treatment history, and overall health status. This involves a thorough evaluation of the patient's medical records, physical examination, and relevant laboratory tests.\n*   **Apheresis:** Overseeing the process of apheresis, where the patient's T cells are collected from their blood. This procedure involves separating the T cells from other blood components and returning the remaining blood to the patient.\n*   **CAR-T Cell Engineering:** This is where Dr. Sadelain's expertise is most crucial. He likely directs the laboratory process of genetically modifying the patient's T cells to express a chimeric antigen receptor (CAR) on their surface. This CAR is designed to recognize a specific protein (antigen) that is present on the surface of cancer cells. The most common CAR targets are CD19 for certain lymphomas and leukemias, and BCMA for multiple myeloma. The engineering process involves using viral vectors, typically lentiviruses, to introduce the CAR gene into the T cells.\n*   **CAR-T Cell Expansion:** After the T cells have been genetically modified, they are expanded in the laboratory to generate a large number of CAR-T cells. This process can take several weeks and requires careful monitoring to ensure the cells are healthy and functional.\n*   **Patient Conditioning:** Before the CAR-T cells are infused back into the patient, they typically undergo a conditioning regimen, usually involving chemotherapy. This helps to suppress the patient's immune system and create space for the CAR-T cells to expand and function effectively.\n*   **CAR-T Cell Infusion:** The CAR-T cells are infused back into the patient through an intravenous line. This is a critical step that requires careful monitoring for potential infusion-related reactions.\n*   **Post-Infusion Monitoring and Management:** After the CAR-T cells have been infused, the patient is closely monitored for signs of efficacy and toxicity. Common toxicities associated with CAR-T cell therapy include cytokine release syndrome (CRS) and neurotoxicity. Dr. Sadelain would be skilled in managing these complications, using medications such as tocilizumab and corticosteroids. He would also monitor the patient for long-term complications, such as B cell aplasia and hypogammaglobulinemia.\n\nHis expertise extends beyond the technical aspects of CAR-T cell therapy to encompass the broader aspects of patient care, including managing treatment-related complications, providing supportive care, and communicating effectively with patients and their families.\n\n### 4. Academic Contributions & Research\n\nDr. Sadelain's influence extends far beyond his clinical practice. He is a prominent figure in academic research, with a significant body of publications in leading medical journals. His research focuses on the development and optimization of CAR-T cell therapies, exploring ways to improve their efficacy, reduce toxicity, and expand their applicability to a wider range of cancers.\n\nHis research likely encompasses several key areas:\n\n*   **CAR Design and Optimization:** Investigating different CAR designs to improve their binding affinity, specificity, and signaling capabilities. This involves exploring different antigen-binding domains, hinge regions, transmembrane domains, and intracellular signaling domains.\n*   **T Cell Engineering Strategies:** Exploring novel methods for engineering T cells, including the use of different viral vectors, gene editing technologies, and non-viral delivery systems.\n*   **Overcoming Resistance Mechanisms:** Investigating the mechanisms by which cancer cells develop resistance to CAR-T cell therapy and developing strategies to overcome these mechanisms. This includes targeting multiple antigens, engineering CAR-T cells to secrete cytokines or chemokines, and combining CAR-T cell therapy with other immunotherapies.\n*   **Expanding CAR-T Cell Therapy to Solid Tumors:** Developing CAR-T cell therapies that can effectively target solid tumors, which have proven to be more challenging than hematological malignancies. This involves addressing issues such as tumor heterogeneity, limited T cell infiltration, and immunosuppressive tumor microenvironments.\n*   **Managing CAR-T Cell Therapy Toxicities:** Developing strategies to prevent and manage the toxicities associated with CAR-T cell therapy, such as cytokine release syndrome (CRS) and neurotoxicity. This includes developing novel biomarkers for predicting toxicity and exploring new therapeutic interventions.\n\nHis publications would likely include preclinical studies demonstrating the efficacy of novel CAR-T cell constructs in animal models, as well as clinical trials evaluating the safety and efficacy of CAR-T cell therapy in human patients. His research has undoubtedly had a significant impact on the field of CAR-T cell therapy, contributing to the development of more effective and safer treatments for cancer.\n\n### 5. Patient Impact & Community Work\n\nWhile the specifics of Dr. Sadelain's patient interactions are confidential, his contributions to the field of CAR-T cell therapy have undoubtedly had a profound impact on the lives of countless individuals battling cancer. The success stories of patients who have achieved long-term remission following CAR-T cell therapy are a testament to the transformative potential of this innovative approach.\n\nBeyond his direct patient care, Dr. Sadelain likely contributes to the community through various activities, such as participating in cancer awareness campaigns, educating the public about CAR-T cell therapy, and advocating for policies that support cancer research and access to innovative treatments. He may also be involved in mentoring young scientists and clinicians, inspiring the next generation of leaders in the field of immunotherapy.\n\nHis involvement in clinical trials also directly benefits patients. By participating in these trials, patients have access to cutting-edge treatments that may not be available elsewhere. Furthermore, the data generated from these trials helps to advance the field of CAR-T cell therapy and improve outcomes for future patients.\n\n### 6. Legacy and Future Outlook\n\nDr. Michel Sadelain stands as a pivotal figure in the evolution of cancer immunotherapy. His pioneering work in CAR-T cell engineering has not only revolutionized the treatment of certain hematological malignancies but has also paved the way for the development of new immunotherapies for a broader range of cancers. His legacy is cemented in the improved survival rates and enhanced quality of life experienced by patients who have benefited from CAR-T cell therapy.\n\nHis influence extends beyond his direct clinical and research contributions. He has inspired countless scientists and clinicians to pursue careers in cancer immunotherapy, fostering a vibrant and growing field of research and development. His dedication to innovation and his commitment to patient care have set a new standard for excellence in medical science.\n\nLooking to the future, Dr. Sadelain's work will likely continue to shape the landscape of cancer treatment. His ongoing research efforts will undoubtedly lead to further improvements in CAR-T cell therapy, making it more effective, safer, and accessible to a wider range of patients. He will likely play a key role in expanding the applications of CAR-T cell therapy to solid tumors, developing new strategies to overcome resistance mechanisms, and personalizing treatment approaches based on individual patient characteristics.\n\nDr. Sadelain's unwavering dedication to advancing medical science and his unwavering commitment to improving the lives of cancer patients ensure that his legacy will endure for generations to come. He is not only a skilled physician and researcher but also a visionary leader who has transformed the way we think about and treat cancer.\n",
  "bioGenerated": true
}